Literature DB >> 27428795

Pulmonary arterial hypertension in schistosomiasis.

Francisca Gavilanes1, Caio J C Fernandes, Rogerio Souza.   

Abstract

PURPOSE OF REVIEW: Schistosomiasis is one of the most prevalent parasitic diseases in the world, being present in more than 70 countries. Pulmonary hypertension is one of the several chronic complications of schistosomiasis; particularly in developing countries, schistosomiasis-associated pulmonary arterial hypertension might represent one of the most prevalent causes of pulmonary arterial hypertension. RECENT
FINDINGS: New epidemiological data reinforce the importance of schistosomiasis in the context of pulmonary hypertension; furthermore, the inflammatory components of the pathophysiology of pulmonary hypertension associated with schistosomiasis have been recently explored, opening the perspective of new targets to be explored. Clinical and hemodynamic features of this particular complication of schistosomiasis, and the role of targeted therapies in this setting, have been better described in recent years.
SUMMARY: The importance of schistosomiasis-associated pulmonary hypertension is now recognized with better knowledge about its pathophysiology and management. Nevertheless, there is a need for better understanding the predisposal factors (genetic, environmental and so on) for the development of pulmonary hypertension in schistosomiasis as a way to prevent it from occurring. Furthermore, better control programs to decrease disease transmission are still missing, ensuring that we will have to face this devastating complication of schistosomiasis for a long future.

Entities:  

Mesh:

Year:  2016        PMID: 27428795     DOI: 10.1097/MCP.0000000000000300

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  7 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice.

Authors:  Guilin Chen; Shengkai Zuo; Juan Tang; Caojian Zuo; Daile Jia; Qian Liu; Guizhu Liu; Qian Zhu; Yuanyang Wang; Jian Zhang; Yujun Shen; Dongrui Chen; Ping Yuan; Zhiqiang Qin; Chengchao Ruan; Jue Ye; Xiao-Jian Wang; Yuping Zhou; Pingjin Gao; Peng Zhang; Jinming Liu; Zhi-Cheng Jing; Ankang Lu; Ying Yu
Journal:  J Exp Med       Date:  2018-07-03       Impact factor: 14.307

Review 3.  The Role of Type 2 Inflammation in Schistosoma-Induced Pulmonary Hypertension.

Authors:  Claudia S Mickael; Brian B Graham
Journal:  Front Immunol       Date:  2019-01-24       Impact factor: 7.561

Review 4.  Schistosomiasis Pulmonary Arterial Hypertension.

Authors:  Jean Pierre Sibomana; Aloma Campeche; Roberto J Carvalho-Filho; Ricardo Amorim Correa; Helena Duani; Virginia Pacheco Guimaraes; Joan F Hilton; Biruk Kassa; Rahul Kumar; Michael H Lee; Camila M C Loureiro; Sula Mazimba; Claudia Mickael; Rudolf K F Oliveira; Jaquelina S Ota-Arakaki; Camila Farnese Rezende; Luciana C S Silva; Edford Sinkala; Hanan Yusuf Ahmed; Brian B Graham
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

5.  Schistosomiasis & Heart - On Behalf of the Neglected Tropical Diseases and other Infectious Diseases affecting the Heart (the NET-Heart Project).

Authors:  Edith Liliana Posada-Martínez; Luis Gerardo Gonzalez-Barrera; Kiera Liblik; Juan Esteban Gomez-Mesa; Clara Saldarriaga; Juan Maria Farina; Josefina Parodi; Zier Zhou; Manuel Martinez-Selles; Adrian Baranchuk
Journal:  Arq Bras Cardiol       Date:  2022-05       Impact factor: 2.667

6.  Th2 CD4+ T Cells Are Necessary and Sufficient for Schistosoma-Pulmonary Hypertension.

Authors:  Rahul Kumar; Claudia Mickael; Biruk Kassa; Linda Sanders; Dan Koyanagi; Daniel Hernandez-Saavedra; Scott Freeman; Daniel Morales-Cano; Angel Cogolludo; Amy S McKee; Andrew P Fontenot; Ghazwan Butrous; Rubin M Tuder; Brian B Graham
Journal:  J Am Heart Assoc       Date:  2019-07-24       Impact factor: 5.501

7.  Pulmonary Hypertension in General Cardiology Practice.

Authors:  Daniela Calderaro; José Leonidas Alves Junior; Caio Júlio César Dos Santos Fernandes; Rogério Souza
Journal:  Arq Bras Cardiol       Date:  2019-10-10       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.